It’s been a miserable week for investors in clinical-stage biotechnology company Cassava Sciences (SAVA). The stock tumbled over 20% following a fireside chat, where CEO Remi Barbier outlined the prog...
It’s been a miserable week for investors in clinical-stage biotechnology company Cassava Sciences (SAVA). The stock tumbled over 20% following a fireside chat, where CEO Remi Barbier outlined the prog...